Truist analyst Srikripa Devarakonda lowered the firm’s price target on Verastem to $34 from $39 and keeps a Buy rating on the shares. Ahead of 2024 pivotal readout and regulatory submission in the first half of the year, the stock looks undervalued with potential for upside, the analyst tells investors in a research note. The firm adds however that its updated price target assigns no credit to Copiktra pending additional clarity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VSTM:
- Verastem files $300M mixed securities shelf
- Verastem reports Q3 adjusted EPS (71c), consensus (84c)
- Verastem announces results from avutometinib, defactinib trial at IGCS 2023
- Verastem announces initial results of RAMP 203 trial of avutometinib, LUMAKRAS
- Verastem presents avutometinib and defactinib combination program updates
